Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Up 28.0% in December

Sutro Biopharma, Inc. (NASDAQ:STRO) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 3,150,000 shares, a growth of 28.0% from the December 15th total of 2,460,000 shares. Based on an average daily trading volume, of 925,500 shares, the short-interest ratio is presently 3.4 days.

Sutro Biopharma Stock Up 8.6 %

STRO stock traded up $0.16 during midday trading on Friday, hitting $2.01. The company’s stock had a trading volume of 1,309,170 shares, compared to its average volume of 960,843. Sutro Biopharma has a 12 month low of $1.67 and a 12 month high of $6.13. The company has a 50 day moving average of $2.38 and a two-hundred day moving average of $3.33. The firm has a market capitalization of $165.74 million, a price-to-earnings ratio of -1.25 and a beta of 1.15.

Wall Street Analyst Weigh In

STRO has been the subject of a number of research reports. Wedbush reaffirmed an “outperform” rating and set a $8.00 target price on shares of Sutro Biopharma in a report on Tuesday, December 10th. Wells Fargo & Company lowered their target price on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Sutro Biopharma in a research report on Monday, November 18th. Piper Sandler reaffirmed an “overweight” rating and set a $11.00 price objective on shares of Sutro Biopharma in a research report on Friday, October 11th. Finally, JMP Securities reissued a “market outperform” rating and issued a $17.00 target price on shares of Sutro Biopharma in a report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $11.13.

Institutional Trading of Sutro Biopharma

Several hedge funds have recently bought and sold shares of STRO. ProShare Advisors LLC grew its holdings in shares of Sutro Biopharma by 49.1% in the second quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock valued at $48,000 after purchasing an additional 5,373 shares in the last quarter. Hsbc Holdings PLC boosted its position in shares of Sutro Biopharma by 9.7% during the second quarter. Hsbc Holdings PLC now owns 60,858 shares of the company’s stock valued at $173,000 after buying an additional 5,404 shares during the period. SG Americas Securities LLC raised its holdings in shares of Sutro Biopharma by 16.6% in the fourth quarter. SG Americas Securities LLC now owns 40,432 shares of the company’s stock worth $74,000 after buying an additional 5,770 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Sutro Biopharma by 27.4% in the second quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock worth $97,000 after buying an additional 7,082 shares during the period. Finally, Gladius Capital Management LP purchased a new position in Sutro Biopharma during the 3rd quarter valued at $28,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.